Jennifer Barrett, Associate Editor

The therapy is a combination of a checkpoint drug, nivolumab, and a new immune stimulation drug, ALT-803.

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

The triple combination includes a novel cystic fibrosis transmembrane conductance regulator amplifier, third generation corrector, and potentiator.

Pediatric patients treated with larotrectinib in a clinical trial demonstrated a 93% response rate.

An experimental program in Maryland aimed to reduce health care spending by shifting away from hospital-based care and toward less costly, primary, preventive, and outpatient services.

Pharmacists can help optimize medication regimens to produce the best patient outcomes at the lowest cost.

Physicians reported inaccurate self-perceptions when it came to opioid prescribing

Rucaparib demonstrated statistically-significant improvement in progression-free survival for patients in the maintenance treatment setting.

Imraldi, a biosimilar referencing Humira, is expected to launch initially in Europe.

The final rules clarifies several issues important to pharmacists and hints at further rule-making to address direct and indirect remuneration fees.

According to the study, patients who take a reduced dose of abiraterone with a low-fat meal may cut costs by as much as $300,000.

Researchers find that disputed bills amount to $54 billion annually across all health insurers.

Nivolumab plus ipilimumab demonstrated clinical benefit in previously treated patients with dMMR or MSI-H metastatic colorectal cancer.

Despite recent concerns about proton pump inhibitor (PPI) safety, the results of a recently published study found no evidence that PPI use contributes to a higher risk of dementia or Alzheimer disease in older adults.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

For the first time, epilepsy rate estimates have been available for every state, totaling at least 3.4 million individuals living with the disorder.

Officials with the FDA have expanded the approval of Amgen's blinatumomab (Blincyto) to include the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

Blinatumomab (Blincyto) can be used in patients with acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

Childhood obesity may have lasting effects that could permanently alter the likelihood of developing cancer.